WO2004014407A1 - 治療剤 - Google Patents
治療剤 Download PDFInfo
- Publication number
- WO2004014407A1 WO2004014407A1 PCT/JP2003/009978 JP0309978W WO2004014407A1 WO 2004014407 A1 WO2004014407 A1 WO 2004014407A1 JP 0309978 W JP0309978 W JP 0309978W WO 2004014407 A1 WO2004014407 A1 WO 2004014407A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- fraction
- active ingredient
- extract
- added
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 196
- 102000004877 Insulin Human genes 0.000 claims abstract description 98
- 108090001061 Insulin Proteins 0.000 claims abstract description 98
- 229940125396 insulin Drugs 0.000 claims abstract description 98
- 239000004480 active ingredient Substances 0.000 claims abstract description 82
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 66
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 62
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 235000013305 food Nutrition 0.000 claims abstract description 53
- 230000002608 insulinlike Effects 0.000 claims abstract description 53
- 230000004069 differentiation Effects 0.000 claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
- 201000010099 disease Diseases 0.000 claims abstract description 45
- 230000001737 promoting effect Effects 0.000 claims abstract description 30
- 230000001939 inductive effect Effects 0.000 claims abstract description 26
- 230000006362 insulin response pathway Effects 0.000 claims abstract description 24
- 241000208173 Apiaceae Species 0.000 claims description 44
- 240000007087 Apium graveolens Species 0.000 claims description 34
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 34
- 235000010591 Appio Nutrition 0.000 claims description 34
- 235000013361 beverage Nutrition 0.000 claims description 29
- 235000011197 perejil Nutrition 0.000 claims description 23
- 241000208317 Petroselinum Species 0.000 claims description 22
- 230000000069 prophylactic effect Effects 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 17
- 241000196324 Embryophyta Species 0.000 claims description 16
- 239000000411 inducer Substances 0.000 claims description 6
- 244000088415 Raphanus sativus Species 0.000 claims 1
- 239000008103 glucose Substances 0.000 abstract description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 34
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 239000000284 extract Substances 0.000 description 83
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 73
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 70
- 239000000469 ethanolic extract Substances 0.000 description 57
- 230000004190 glucose uptake Effects 0.000 description 57
- 239000000047 product Substances 0.000 description 48
- 238000000034 method Methods 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 31
- 239000013642 negative control Substances 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 239000002024 ethyl acetate extract Substances 0.000 description 27
- 238000000605 extraction Methods 0.000 description 27
- 230000009471 action Effects 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 239000002609 medium Substances 0.000 description 24
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 230000006698 induction Effects 0.000 description 20
- 239000013641 positive control Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 239000007788 liquid Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 241000220259 Raphanus Species 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 238000005194 fractionation Methods 0.000 description 13
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 239000000377 silicon dioxide Substances 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241001211763 Yukara Species 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002481 ethanol extraction Methods 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 102000003746 Insulin Receptor Human genes 0.000 description 5
- 108010001127 Insulin Receptor Proteins 0.000 description 5
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 5
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 5
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 5
- 229940069417 doxy Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229940117336 parsley extract Drugs 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 240000000907 Musa textilis Species 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- -1 for example Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 2
- 244000221633 Brassica rapa subsp chinensis Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- 240000008620 Fagopyrum esculentum Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 235000021438 curry Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- XDSJEBSVZOXUKD-PXBUCIJWSA-N (4r,5s,6r,7r)-4,5,6,7,8-pentahydroxy-3-oxooctanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)CC(O)=O XDSJEBSVZOXUKD-PXBUCIJWSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000954177 Bangana ariza Species 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000183712 Cerinthe major Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 238000001162 G-test Methods 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 241000861914 Plecoglossus altivelis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013531 gin Nutrition 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000012378 hepatocyte growth factor production Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 235000021539 instant coffee Nutrition 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000014537 nerve growth factor production Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010663 parsley oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000013533 rum Nutrition 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019465 surimi Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013522 vodka Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a medicament, food, beverage or feed useful for treating or preventing a disease associated with insulin in a living body, such as diabetes and obesity.
- Insulin is a hormone required for normal mammalian carbohydrate, protein, and fat metabolism. Humans with type I diabetes do not produce enough insulin, a hormone that supports their lives, and require external insulin administration to survive. People with type II diabetes need to administer insulin and insulin secretagogues to control inappropriate blood glucose levels due to factors such as insufficient insulin production and insulin resistance. It becomes. However, among humans with type II diabetes, insulin-induced insulin secretion is promoted in patients with diabetes due to insulin resistance caused by hyperinsulinemia, abnormalities of the insulin receptor, and abnormal downstream signals of the insulin receptor. The treatment may not be effective even if the drug is administered.
- insulin-like substances substances having the same physiological function as insulin (hereinafter sometimes referred to as insulin-like substances) have been developed.
- insulin-like substances for example, Kame i R. and 7 others, Biochem) Commun., 2002, Vol. 292, pages 642-651.
- this Insulin-like substances such as these improve symptoms not only in patients with type I diabetes, but also in patients with type II diabetes, and also with type II diabetes due to insulin resistance, by exhibiting the same physiological activity as insulin. Is expected to.
- Ashitaba is a large perennial herb of the Apiaceae family and is known to have various health-promoting effects.
- the physiological activity of acitapa has antihypertensive effect, antibacterial effect, antitumor effect, gastric acid secretion inhibitory effect, anticancer effect, nerve growth factor production enhancing effect, hepatocyte growth factor production enhancing effect.
- insulin-like actions such as antidiabetic action and antiobesity action have not been known so far.
- Celery is a plant belonging to the Umbelliferae family and known for various physiological effects. As the physiologic action of celery, anticoagulant action, carcinostatic action and the like are known. However, insulin-like actions such as antidiabetic action and antiobesity action have not been known so far.
- Parsley is a plant belonging to the Apiaceae family and known for various physiological effects.
- Known physiological effects of parsley include anemia amelioration, food poisoning prevention, hemostasis, recovery from fatigue, sweating, diuresis, and heat retention.
- insulin-like actions such as anti-diabetic action and anti-obesity action have not been known so far. Disclosure of the invention
- An object of the present invention is to develop a plant-derived processed product having an insulin-like action suitable for food materials and pharmaceutical materials that is safe and easily ingested from natural products, and uses the processed product to produce a pharmaceutical product. , Food, beverage or feed.
- a first invention of the present invention is a therapeutic or preventive agent for a disease associated with modulation of the amount of insulin or insulin response, characterized by containing a processed product derived from a Umbelliferae plant as an active ingredient. Agent.
- a processed product derived from a Umbelliferae plant is contained as an active ingredient. And an insulin-mimetic agent.
- the third invention of the present invention relates to a food, beverage or feed for treating or preventing a disease associated with modulation of the amount of insulin or insulin response, which comprises a processed product derived from a Umbelliferae plant as an active ingredient.
- the fourth invention of the present invention relates to an agent for promoting the uptake of glucose into cells, which comprises a processed product derived from a Umbelliferae plant as an active ingredient.
- the fifth invention of the present invention relates to an agent for inducing differentiation into adipocytes, which comprises a processed product derived from a Umbelliferae plant as an active ingredient.
- examples of the Umbelliferae plants include, for example, basin, celery, and parsley. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a graph showing the amount of biosynthesis of tridaliceride in adipocytes which has been induced to differentiate by the fraction extracted from the roots of Asaba.
- FIG. 2 is a diagram showing the amount of triglyceride biosynthesis in adipocytes induced to differentiate by fractions 3 and 4 of the fraction extracted from the root extract of Ashitapa.
- FIG. 3 is a graph showing the action of promoting glucose uptake by the extract fraction of Ashitaba root.
- FIG. 4 is a graph showing the amount of biosynthesis of tridaliceride in adipocytes that has been induced to differentiate by the fraction extracted from Ashitapa leaves.
- FIG. 5 is a graph showing the amount of triglyceride biosynthesis in adipocytes induced to differentiate by the celery leaf extract fraction.
- FIG. 6 is a graph showing the glucose uptake promoting effect of a celery leaf extract fraction.
- FIG. 7 is a graph showing the amount of triglyceride biosynthesis in adipocytes induced to differentiate by the parsley extract fraction.
- FIG. 8 is a graph showing the action of promoting glucose uptake by the parsley extract fraction.
- FIG. 9 is a graph showing the amount of toridaricelide biosynthesis in adipocytes induced to differentiate by the Ashitaba root extract fraction.
- FIG. 10 is a graph showing the action of promoting glucose uptake by a fraction extracted from roots of radish.
- FIG. 11 is a diagram showing the action of promoting glucose uptake by a fraction extracted from the leaves of abaca leaf.
- FIG. 12 is a graph showing the glucose uptake-promoting action of the fraction obtained from the fraction of the root extract of radish.
- FIG. 13 is a graph showing the inhibitory effect of cytochalasin B on the promotion of glucose uptake by the ethanol extract fraction of the roots of Acitapa.
- FIG. 14 is a diagram showing the synergistic effect of the ethanol extract fraction of radish root and insulin to promote glucose uptake.
- FIG. 15 is a graph showing the action of promoting glucose uptake by insulin stimulation in adipocytes that have been induced to differentiate by the fraction extracted with ethanol from the roots of Acitapa.
- FIG. 16 is a graph showing the amount of biosynthesis of todari seride in adipocytes induced to differentiate by the extract of A. tapa foliage.
- the Umbelliferae plant is a plant belonging to the angiosperm Umbelliferae, and includes, for example, asiatica, seri, honeywort, shishido, carrot, celery, parsley and the like.
- ash tapa, celery, and parsley can be particularly preferably used. In the present invention, these can be used alone or as a mixture of two or more.
- the Umbelliferae plants used in the present invention are not particularly limited, but fruits, seeds, seed coats, flowers, leaves, stems, roots, rhizomes and / or whole plants can be used as they are. it can.
- the processed product derived from a Umbelliferae plant used as an active ingredient in the present invention is not particularly limited as long as it has an insulin-like action.
- Examples thereof include an extract, a pulverized product, a squeezed liquid, a crushed product, and a chemical treatment.
- Each treated product can be used alone or in combination of two or more.
- the insulin-like action is not particularly limited as long as it shows a physiological activity equivalent to that of insulin. And metabolic regulation such as promotion of sugar and amino acid uptake, glycogen, protein synthesis and degradation of the protein.
- At least an action of inducing differentiation into adipocytes or an action of promoting glucose uptake into cells may be exhibited.
- the presence or absence of such an insulin-like action can be easily measured by the method described in Example 3 or 5 described below.
- an extract refers to a substance obtained through a step of performing an extraction operation using an extraction solvent.
- the extraction can be performed as follows by a known extraction method. For example, after the raw material is ground or shredded, it can be carried out batchwise or continuously using a solvent.
- the extraction solvent used to obtain the extract water, alcohols such as chloroform, ethanol, methanol, and isopropyl alcohol; ketones such as acetone and methyl ethyl ketone; methyl acetate; and vinegar.
- Hydrophilic or lipophilic solvents such as ethyl ether can be used, and they can be used alone or as a mixed solution as required.
- the amount of the extraction solvent may be appropriately determined, but usually, the extraction solvent is preferably used in an amount of 0.1 to 100 times the weight of the raw material (solid content).
- the extraction temperature may be appropriately determined according to the purpose. In the case of water extraction, the temperature is usually preferably from 4 to 130, more preferably from 25 to 100 ° C. When ethanol is contained in the solvent, the temperature range is 4 to 60 ° C. It is suitable.
- the extraction time may be determined in consideration of the extraction efficiency, but usually, the raw material, the extraction solvent, and the extraction temperature are set so as to be preferably in the range of several seconds to several days, more preferably in the range of 5 minutes to 24 hours. Is preferred.
- the extraction operation may be performed, for example, while stirring or standing, and may be repeated several times as necessary.
- an extract derived from a Umbelliferae plant (hereinafter sometimes referred to as the extract of the present invention) is obtained.
- the extract can be subjected to filtration, centrifugation, concentration, ultrafiltration, molecular sieving, or the like, if necessary, to prepare an extract in which the desired insulin-like substance is concentrated.
- the insulin-like action of the extract or concentrated extract can be easily measured by the method described in Example 3 or 5 described later.
- a plant of the Umbelliferae family is made into a tea leaf by a known method, and an extract using the same (for example, ashitapa tea) can also be used as the extract of the present invention as long as it has an insulin-like action.
- two or more of these extracts can be used.
- two or more kinds of extracts obtained by different extraction methods may be used and used.
- an extract derived from a Umbelliferae plant is fractionated by a known method.
- the fraction obtained by arbor and the fraction obtained by repeating the fractionation operation a plurality of times are also included in the extract of the present invention.
- the above fractionation means include extraction, fractional precipitation, column chromatography, thin-layer chromatography, and the like.
- a plant can be dried and ground to obtain a powdery ground material derived from a Umbelliferae plant. . Drying is preferably performed by freeze-drying. Further, a pulverized product may be obtained by freeze pulverization.
- the method for producing a squeezed liquid derived from a Umbelliferae plant is not particularly limited as long as it is a known method of squeezing a plant.
- a squeezing machine such as a screw type, a gear type, or a cutter type is used.
- Juice can be squeezed using a juicer.
- the juice can be obtained by shredding or grinding as a pretreatment and squeezing with the above-mentioned juicer or cloth.
- a crushed product is a product obtained by crushing a Umbelliferae plant, and generally has a larger piece of tissue than a crushed product, and can be produced, for example, by using a crusher.
- the chemically treated product is not particularly limited, but refers to a product obtained by subjecting a Umbelliferae plant to an acid treatment, an alkali treatment, an oxidation treatment, a reduction treatment, and the like.
- hydrochloric acid, sulfuric acid, nitric acid, copper It can be produced by immersing a Umbelliferae plant in an aqueous solution containing an inorganic or organic acid such as citric acid or acetic acid, or an inorganic or organic base such as sodium hydroxide, potassium hydroxide, or ammonia.
- Chemically treated products include all those derived from plants that have undergone such chemical treatment.
- Enzyme-treated products include, for example, enzyme-treated products of pectinase, cellulase, xylanase, amylase, mannanase, dalcosidase, etc., and enzyme-reacted products of microorganisms (eg, fermented products). Can be produced by allowing the above enzyme to act in an appropriate buffer. Enzyme-treated products include all those derived from plants that have been subjected to the enzyme treatment as described above. Further, the processed product derived from a Umbelliferae plant includes, for example, a juice obtained by cutting the stem of a Umbelliferae plant and obtaining the cut surface.
- the shape of a processed product derived from a Umbelliferae plant is not particularly limited as long as it has an insulin-like effect, but may be any of powder, solid, and liquid forms.
- the substance can be granulated by a known method and used as a granular plant-derived treated product of the present invention as a granular solid.
- the granulation method is not particularly limited. Rolling granulation, stirring granulation, fluidized bed granulation, airflow granulation, extrusion granulation, compression molding granulation, crushing granulation, spray granulation or spray granulation Grains and the like are exemplified.
- the powdered processed product of the Umbelliferae-derived plant may be dissolved in a liquid, for example, water or alcohol to make a liquid, and used as the processed material of the present invention.
- the active ingredient itself may be, for example, a food for treating or preventing a disease associated with modulation of the amount of insulin or insulin response described in the present specification. It can be used as beverage, feed, etc.
- Examples of the mode of using the active ingredient itself include those in which the extract, the pulverized product, and the like are in the form of tablets.
- the tablet may be produced according to a known tableting method.
- the present invention provides a food, drink or feed containing a processed product derived from a Umbelliferae plant at a high concentration or high purity, which is compared with conventional foods, drinks or feeds. Or it means that the feed contains an insulin-like substance at a high concentration and / or high purity.
- Such foods, beverages or feeds can be produced, for example, by incorporating the active ingredient of the present invention into conventional foods and the like as described below.
- a processed product derived from a Umbelliferae plant is referred to as an active ingredient of the present invention, and a therapeutic or prophylactic agent for a disease associated with modulation of the amount of insulin or insulin response containing the active ingredient of the present invention is treated according to the present invention. It may be referred to as an agent or a prophylactic agent.
- the active ingredient according to the present invention has no particular toxicity as described below. Also, there is no worry about side effects. Therefore, it is possible to safely and appropriately treat or prevent the disease. Therefore, the therapeutic agent, prophylactic agent, food, beverage or feed of the present invention comprising the active ingredient is effective for treating or preventing a disease associated with modulation of insulin amount or insulin response.
- diseases associated with modulation of insulin amount or insulin response include changes in blood insulin level, changes in insulin or insulin receptor activity levels, abnormalities in insulin receptor downstream signals, and the like.
- diabetes include both type I diabetes and type II diabetes.
- insulin resistance is such that administration of an insulin stimulant induces no therapeutic effect. Is also included for diseases caused by
- Insulin is known to promote the induction of preadipocyte differentiation into adipocytes, and it is known that mature adipocytes take up glucose and accumulate triglycerides in cells (Rub in CS et al., J. Bio 1. Chem., Vol. 253, No. 20, P 7570-7578 (1978)).
- a test substance can be administered instead of insulin, and the insulin-like action of the test substance can be measured by measuring the differentiation into adipocytes and the amount of triglyceride biosynthesis in the cells. it can.
- Insulin is also known to promote glucose uptake, and it is known that the action of insulin promotes glucose uptake in mature fat cells (Rub in CS et al., J. B. iol. Chem., Vol. 253, No. 20, P 7579—7583 (1978)). In other words, using this method, it is possible to measure the insulin-like action of the test substance by administering the test substance instead of insulin and measuring the amount of glucose uptake in the mature fat cells. it can.
- Examples of the therapeutic or prophylactic agent of the present invention include those obtained by formulating the active ingredient of the present invention in combination with a known pharmaceutical carrier.
- the production of the therapeutic or prophylactic agent of the present invention is usually carried out by blending the active ingredient with a pharmaceutically acceptable liquid or solid carrier, and if desired, a solvent, a dispersant, an emulsifier, a buffer, Stabilizers, excipients, binders, disintegrants, lubricants, etc., and solid preparations such as tablets, granules, powders, powders, and capsules, and liquid preparations such as ordinary liquid preparations, suspensions, and emulsions can do. It can also be used as a dried product which can be made into a liquid form by adding an appropriate carrier before use, or as an external preparation.
- the pharmaceutical carrier can be selected according to the administration form and dosage form of the therapeutic or prophylactic agent.
- an oral preparation comprising a solid composition
- tablets, pills, capsules, powders, fine granules, granules and the like can be used.
- starch, lactose, sucrose , Mannitol, carboxymethylcellulose, corn starch, inorganic salts, etc. are used.
- a binder, a disintegrant, a surfactant, a lubricant, a fluidity promoter, a flavoring agent, a coloring agent, a fragrance, and the like can be further blended.
- tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, or a film of a gastric or enteric substance, if desired.
- a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, or a film of a gastric or enteric substance
- an oral preparation composed of a liquid composition it can be a pharmacologically acceptable emulsion, solution, suspension, syrup, etc.For example, purified water, ethanol, etc. are used as carriers Is done.
- auxiliary agents such as wetting agents and suspending agents, sweetening agents, flavoring agents, preservatives and the like may be added.
- a parenteral preparation when used, distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, and the like, as the diluent, the active ingredient of the present invention in a usual manner. It can be prepared by dissolving or suspending in corn oil, propylene glycol, polyethylene glycol, or the like, and adding a bactericide, a stabilizer, an isotonic agent, a soothing agent, and the like, if necessary. In addition, a solid composition can be prepared and dissolved in sterile water or a sterile solvent for injection before use.
- External preparations include solid, semi-solid or liquid preparations for transdermal administration or transmucosal (oral, nasal) administration. Suppositories are also included.
- emulsion preparations such as emulsions and lotions
- liquid preparations such as tinctures for external use
- liquid preparations for transmucosal administration ointments
- ointments such as oily ointments and hydrophilic ointments
- transdermal preparations such as films, tapes and cataplasms It can be a patch for administration or transmucosal administration.
- each of the above-mentioned various preparations can be appropriately produced by a conventional method using a known pharmaceutical carrier or the like.
- the content of the active ingredient in such a preparation is not particularly limited as long as the active ingredient can be administered in the dosage range described below, preferably in consideration of the dosage form, administration method, and the like. is not.
- the therapeutic or prophylactic agent of the present invention is administered by an appropriate route depending on the form of the preparation.
- the administration method is also not particularly limited, and can be internal, external, or injection.
- injection The preparation can be administered, for example, intravenously, intramuscularly, subcutaneously, intradermally, and the like.
- a suppository may be administered by a suitable administration method.
- the dose of the therapeutic or prophylactic agent of the present invention is appropriately determined depending on the form of the preparation, the administration method, the purpose of use, and the age, weight, and symptoms of the patient to whom the therapeutic or prophylactic agent is administered, and is not constant. .
- the dose of the active ingredient contained in the formulation is preferably 0.1 / g to 1 g / kg of human (eg, adult) per day.
- the administration may be performed once or several times a day within the desired dose range.
- the therapeutic or prophylactic agent of the present invention can be orally administered as it is, or can be added to any food or drink for daily ingestion.
- the active ingredient of the present invention when used in combination with a substance having an action equivalent to that of the active ingredient of the present invention, for example, insulin, a synergistic effect of these can be expected as described in Example 20. .
- the present invention can also provide an insulin-like agent containing the active ingredient.
- the insulin-like agent may be the active ingredient itself, or may be a composition containing the active ingredient.
- the insulin-mimetic agent is prepared by, for example, blending the active ingredient with another ingredient (for example, insulin or the like) that can be used for the same purpose as the active ingredient, and the like. It may be manufactured in the form of a commonly used reagent.
- the content of the above-mentioned active ingredient in the insulin-mimetic agent is such an amount that the desired effect of the present invention can be obtained in consideration of the administration method, purpose of use, and the like of the insulin-mimetic agent. Well, it is not particularly limited.
- the content of the active ingredient is, for example, 0.01 to 100% by weight.
- the amount of the insulin-like agent used is not particularly limited as long as the desired effect of the present invention can be obtained.
- it is preferable to administer the active ingredient in the therapeutic or prophylactic agent. It may be used in such an amount that the active ingredient can be administered within the dosage range.
- Insulin-like agents are useful in diseases involving modulation of insulin levels or insulin response.
- the insulin-mimetic agent can also be used for producing a food, drink or feed for treating or preventing these diseases. These foods, drinks or feeds can be used in accordance with the above-mentioned foods, drinks or feeds for treating or preventing a disease accompanied by modulation of insulin amount or insulin response.
- the insulin-like agent is also useful for screening a drug for a disease associated with modulation of insulin amount or insulin response.
- the insulin-like agent is also useful for studying the mechanism of action of insulin on cells, and for studying functions related to physical changes in the cells.
- the insulin-mimetic agent of the present invention can also be used as an agent for treating or preventing a disease that requires a decrease in the amount of insulin for treatment or prevention.
- the disease is not particularly limited, and examples thereof include hyperinsulinemia and Alzheimer's disease.
- insulin receptor-mediated stimulation and life-span effect there is a close relationship between insulin receptor-mediated stimulation and life-span effect (Science, vol. 299, pp. 572-574 (2003); Nature, vol. 424, P 277-284 (2003)), and the insulin-like agent of the present invention can also be used as an anti-aging agent.
- the active ingredient according to the present invention has no particular toxicity as described below. Also, there is no concern about side effects. Therefore, an insulin-like action can be safely and appropriately expressed. Therefore, the medicament, food, drink or feed of the present invention comprising the active ingredient is effective for treating or preventing a disease associated with modulation of insulin amount or insulin response.
- the present invention provides a food or drink for treating or preventing a disease accompanied by modulation of the amount of insulin or insulin response containing, added or diluted with the active ingredient.
- Food or feed is provided.
- the food, beverage or feed of the present invention is extremely useful for ameliorating or preventing symptoms of a disease accompanied by modulation of insulin amount or insulin response due to its insulin-like action.
- the food or beverage of the present invention is a food or beverage for lowering blood glucose level, which has an action of lowering blood glucose level, and is effective for those who are concerned about blood glucose level and those who are concerned about body fat. It is useful as a functional food or beverage.
- containing means that the active ingredient used in the present invention is contained in a food, beverage or feed
- additional means that the raw material of the food, beverage or feed contains the active ingredient used in the present invention.
- concentration refers to a mode of adding a raw material of food, beverage or feed to the active ingredient used in the present invention.
- the method for producing the food, beverage or feed of the present invention is not particularly limited.
- compounding, cooking, processing, etc. may follow those of general foods, beverages or feeds, and can be produced by such a manufacturing method. It suffices if the active ingredient according to the present invention is contained.
- the food or beverage of the present invention is not particularly limited, for example, processed cereals (processed flour, processed starch, processed premix, classified ⁇ , etc.) containing the active ingredient according to the present invention. Macaroni, breads, bean jam, buckwheat, fu, rice noodles, wrapped rice cake, etc., processed fats and oils (plastic oil, tempura oil, salad oil, mayonnaise, dressing, etc.), processed soybeans (tofu) , Miso, natto, etc.), processed meat products (ham, bacon, pressed ham, sausage, etc.), marine products (frozen surimi, kamaboko, chikuwa, hampan, sweetfish fried, tuna, streaks, fish meat ham, sausage, bonito, fish) Egg products, canned marine products, tsukudani, etc., dairy products (raw milk, cream, yogurt, butter, cheese, condensed milk) Milk powder, ice cream, etc.), processed vegetables and fruits (pastes, jams, pickles, fruit drinks,
- Frozen foods (Sukiyaki, Chawanmushi, Unagikaba-yaki, Hamburg steak, Shimai, Gyoza, Various Sticks, fruit capsules), solid foods, liquid foods (such as soups), spices, and other agricultural / forestry products, livestock products, and processed fish products.
- the food or beverage of the present invention contains the above-mentioned active ingredient (s) alone or in a plurality, contains, is added, or is diluted, as long as the content corresponds to a necessary amount for expressing an insulin-like action.
- active ingredient s
- beverage of the present invention can also be mixed with the active ingredient of the present invention and a squeezed liquid of a plant other than Apiaceae, for example, vegetables or fruits, or squeezed simultaneously with a Upiaceae plant to form a health drink. .
- the content of the active ingredient in the food or beverage of the present invention is not particularly limited, and can be appropriately selected from the viewpoints of its functionality and activity.
- it is preferably 0.000% by weight per 100% by weight of the food. 0 1% by weight or more, more preferably 0.001 to 10% by weight, It is preferably 0.0006 to 6% by weight, for example, preferably 0.00001% by weight or more, more preferably 0.0001% or more per 100% by weight of beverage; L 0% by weight, more preferably 0% by weight. 0006 to 6% by weight.
- the food or beverage of the present invention preferably contains an active ingredient contained therein, for example, in a human (for example, adult) daily of 00 lmg to; L 0 gZkg, preferably 0.1 mg to: IgZkg. Ingest it as you like.
- the content of the active ingredient is, for example, 0.01 to 100% by weight.
- the content of the active ingredient of the present invention is, for example, 0.01 to 100% by weight.
- the present invention provides a feed for living organisms having an insulin-like action, comprising, adding and Z or diluting the active ingredient.
- the present invention also provides a method of breeding an organism, which comprises administering the compound to the organism.
- an agent for breeding a living being characterized by containing the active ingredient.
- the organisms are, for example, farm animals, pet animals, and the like, and the farm animals include livestock, laboratory animals, poultry, fish, crustaceans, and shellfish.
- the feed include a feed for maintaining and / or improving physical condition.
- the breeding agent include an immersion agent, a feed additive, and a beverage additive.
- the same effects as those of the therapeutic or prophylactic agent of the present invention can be obtained, based on the insulin-like action of the active ingredient used in the present invention, in the organism as exemplified above to which they are applied.
- the active ingredient used in the present invention is usually administered in a body weight of 1 kg of a target organism, preferably 0.01 to 200 Omg per day. Administration may be, for example,
- the mixture can be added to and mixed with the raw material of the artificial blended feed to be provided to the target organism, or can be mixed with the powdered raw material of the artificial blended feed and then further added to and mixed with other raw materials.
- the content of the active ingredient in the feed is not particularly limited, and may be appropriately set according to the purpose, but a ratio of 0.001 to 15% by weight is suitable.
- the method for producing the feed of the present invention is not particularly limited, and the composition may be the same as that of a general feed.
- the produced feed contains the active ingredient according to the present invention having an insulin-like action. Just fine.
- the organism to which the present invention can be applied is not limited. Poultry such as chickens, chickens, ducks, turkeys and ostriches, and pet animals such as dogs and cats are widely applicable.
- the present invention can also provide a glucose uptake promoter into cells containing the active ingredient.
- the glucose uptake promoter may be the active ingredient itself, or may be a composition containing the active ingredient.
- the glucose uptake enhancer is prepared by blending the active ingredient with another ingredient (for example, insulin or the like) which can be used for the same purpose as the active ingredient, and is usually prepared according to the above-mentioned method for producing a therapeutic or prophylactic agent. It may be manufactured in the form of the reagent used.
- the content of the active ingredient in the glucose uptake promoter should be such that the desired effect of the present invention can be obtained in consideration of the administration method, purpose of use, and the like of the glucose uptake promoter. Well, it is not particularly limited.
- the amount is, for example, 0.01 to 100% by weight.
- the amount of the glucose uptake promoter used is not particularly limited as long as the desired effect of the present invention can be obtained.
- it is preferably used in such an amount that the active ingredient can be administered within the range of the dose of the active ingredient in the therapeutic or prophylactic agent.
- the glucose uptake promoting agent is useful for treating or preventing a disease that requires a glucose uptake promoting effect on cells for treatment or prevention. Examples of the disease include, in addition to the above-mentioned diseases accompanied by the modulation of the amount of insulin or insulin response, heart diseases, in particular, myocardial infarction and cardiac damage after ischemia.
- the glucose uptake promoter promotes glucose uptake by cells, the action of muscle glucose cells can induce muscle strengthening action and fatigue recovery action.
- the glucose uptake promoter can also be used for the production of foods, drinks or feeds for treating or preventing these diseases. These foods, drinks or feeds can be used in accordance with the above-mentioned foods, drinks or feeds for treating or preventing the above-mentioned diseases accompanied by modulation of insulin amount or insulin response.
- the glucose uptake promoter is also useful for screening a drug for a disease that requires a glucose uptake promoting effect on cells for the above treatment or prevention. Further, the glucose uptake promoter is also useful for studying the mechanism of glucose uptake by cells and for studying functions such as physical changes of the cells.
- the present invention can also provide an agent for inducing differentiation into an adipocyte containing the active ingredient.
- the progenitor cells which the differentiation inducer can induce differentiation into adipocytes are not particularly limited as long as they are cells capable of differentiating into adipocytes. No.
- the differentiation inducer may be the active ingredient itself, or may be a composition containing the active ingredient.
- the differentiation inducer is prepared by, for example, mixing the active ingredient with another ingredient (eg, insulin or the like) that can be used for the same purpose as the active ingredient, and producing the therapeutic or prophylactic agent. It may be produced in the form of a commonly used reagent according to the production method.
- the content of the active ingredient in the differentiation-inducing agent may be an amount capable of achieving the desired effect of the present invention, taking into account the administration method of the differentiation-inducing agent, the purpose of use, and the like. There is no particular limitation.
- the content of the active ingredient is, for example, 0.01 to 100% by weight.
- the amount of the differentiation inducer used is not particularly limited as long as the desired effect of the present invention can be obtained. In particular, when used by being administered to a living body, it is preferably used in such an amount that the active ingredient can be administered within the range of the dose of the active ingredient in the therapeutic or prophylactic agent.
- the agent for inducing differentiation is useful for treating or preventing a disease that requires an action of inducing differentiation into adipocytes for treatment or prevention.
- the disease examples include, in addition to the above-mentioned diseases accompanied by the modulation of the amount of insulin or insulin response, gout, fatty liver, cholelithiasis, abnormal menstruation, infertility and the like.
- the differentiation inducer can also be used for producing a food, drink or feed for treatment or prevention of these diseases. These foods, drinks or feeds can be used according to the above-mentioned foods, drinks or feeds for treating or preventing a disease accompanied by modulation of insulin amount or insulin response.
- the agent for inducing differentiation is also useful for screening a drug for a disease that requires an action of inducing differentiation into adipocytes for the above treatment or prevention. Further, the agent for inducing differentiation is also useful for studying the mechanism of the action of inducing differentiation into adipocytes, and for studying functions such as physical changes thereof.
- the active ingredient used in the present invention has no toxicity even when administered in an effective amount for the onset of its action.
- no death was observed even if a single dose of ethanol extract of acitapa, celery or parsley was administered to mice at 1 g / kg each.
- no death was observed when the active ingredient was orally administered to rats in a single dose of 1 g / kg / kg.
- Ashica kei-seki (Angelica keiskei) After freeze-drying the roots, 10 g of a finely ground product was added with 10 OmL of clonal form and extracted at room temperature for 30 minutes. After suction filtration, the same operation was repeated for the residue. These extracts were combined under reduced pressure in a single evaporator and evaporated to dryness, and the dried product was dissolved in 2.5 mL of dimethyl sulfoxide to prepare an extract of the root form of Ashitapa root.
- Example 1 10 OmL of ethanol was added to the residue after the extraction of the form of porcine in (1), and extraction was performed at room temperature for 30 minutes. After suction filtration, the same operation was repeated for the residue. The ethanol extracts were combined, concentrated under reduced pressure on a rotary evaporator, and the dried product was dissolved in 2.5 mL of dimethylsulfoxide to prepare a fraction extracted from the residue.
- Example 2 Fractionation of Ashitapa root extract fraction
- Pre-adipocyte cell line 3T3 in Dulbecco's modified Eagle's medium (Sigma, D 6046) (hereinafter A-D-MEM medium) containing 10% fetal serum containing 200 M ascorbic acid (manufactured by Gibco)
- A-D-MEM medium Dulbecco's modified Eagle's medium
- fetal serum containing 200 M ascorbic acid
- Suspend L 1 ATCC CCL—92.1
- the medium was replaced with the same medium.
- On day 7 after replacing the medium with A-D-MEM medium containing 0.25 M dexamethasone, adjust Example 11 to a final concentration of 0.1%.
- the extract extracted from the root form of A. tapa root prepared in (1) or the ethanol extracted fraction from the root of A. tapa prepared in Example 11 (2) was added.
- a category of adding an aqueous solution of 5 mg ZmL insulin (manufactured by Takara Bio Inc.) was set as a positive control, and a category of adding water was set as a negative control.
- the medium was replaced with A—D—MEM medium.
- a 5 mg / mL insulin aqueous solution (1) and water as a negative control were added, and the cells were further cultured for 7 days.
- each well contained 41 extract of root extract from the root of the mouth of ashitaba or ethanol extract of the root of ashitapa, 21 mg of a 5 mg ZmL aqueous solution of insulin as a positive control, and a negative control. Was added as water.
- the amount of triglyceride contained in the solution 101 was measured using a tridariceride G-test (Code 276-69801, manufactured by Wako Pure Chemical Industries, Ltd.). All measurements were performed in duplicate.
- Example 4 Induction of Differentiation into Adipocytes by Fractionation of Fractions of Ashitapa Root Extract It measured according to. As samples, 41 of 2.8 75 mg / mL silica column fractionation fraction 3 or 10.825 mg / mL silica column fractionation fraction 4 were added. The category of addition of a 5 mg / mL insulin aqueous solution of 41 was set as a positive control, and the category of water addition was set as a negative control. Thereafter, the medium and the sample were exchanged in the same manner as described in Example 3, and the amount of triglyceride in the cells was measured 7 days after the addition of the sample.
- the two groups were similar to the group to which insulin was added compared with the negative control in the group to which each concentration of the extract of the form of the ash root of the clonal mouth and the extract of the ash of the base were added.
- Dokishi [1, 2- 3 H (N )] promotes one glucose uptake was found seen. That is, the activity of promoting glucose uptake was observed in the fraction extracted from the form of the roots of the ash roots and the extract of the ethanol extracted from the roots. This is shown in FIG.
- the differentiation-inducing action (insulin-like activity) of the water extract fraction of Acacia oleifera leaf and the ethanol extract of Ashitaba leaf prepared in Example 6 was measured according to the method of Example 3.
- a section was added to which a dimethyl sulfoxide solution was added to a 022% ethanol extract fraction of Ashitaba leaf.
- the category of addition of an aqueous solution of 5/1 5 mg ZmL insulin (Yukara Bio Inc.) was set as a positive control, and the category of addition of dimethyl sulfoxide was set as a negative control. Thereafter, the medium and the sample were exchanged in the same manner as in Example 3, and the amount of triglyceride in the cells was measured 7 days after the addition of the sample.
- Example 3 shows the differentiation-inducing activity (insulin-like activity) of the lipophilic leaf water extract fraction, celery leaf ethanol extract fraction and celery leaf ethyl acetate extract fraction prepared in Example 8 into mature adipocytes. was measured according to the method described above.
- Example 5 was used to evaluate the glucose uptake-promoting effect of the ethanol extract fraction and the ethyl acetate extract fraction obtained from Example 8 and the insulin-like action. According to the method described, the amount of 2-dexoxyglucose uptake into cells during sample stimulation with mature adipocytes was measured.
- a dimethyl sulfoxide solution of a celery leaf ethanol extract fraction or a celery leaf ethyl acetate extract fraction dimethyl sulfoxide solution having a final concentration of 0.2% and 0.066% was added to each well.
- a negative control a group to which no sample was added was set, and as a positive control, a group to which insulin was added so as to have a final concentration of 1 ⁇ g / mL was set.
- 2 were incorporated into the cell - Dokishi [1, 2- 3 H (N )] - to measure the amount of glucose.
- a category was set in which an aqueous solution of a parsley water extraction fraction having a final concentration of 0.4%, 0.2%, or 0.1% was added to each well.
- a category of addition of an aqueous solution of 5 mg ZmL of insulin (manufactured by Yukara Bio Inc.) was set as a positive control, and a category of addition of dimethyl sulfoxide was set as a negative control. Thereafter, the medium and the sample were exchanged in the same manner as in Example 3, and the amount of triglyceride in the cells was measured 7 days after the addition of the sample.
- FIG. 7 shows each sample on the horizontal axis and the amount of biosynthesis of triglyceride (ig / mL) on the vertical axis.
- Example 13 3 Glucose uptake promoting action by parsley extract fraction As an evaluation of glucose uptake promoting action of the parsley ethanol extract fraction and ethyl parsley acetate extract fraction prepared in Example 11, and as an insulin-like action evaluation According to the method described in Example 5, the amount of 2-deoxydalose incorporation into cells during sample stimulation of mature adipocytes was measured.
- a dimethylsulfoxide solution or a parsleyethanol-extracted fraction dimethylsulfoxide solution having a final concentration of 0.2% or 0.066% was used for each well as a sample.
- a negative control a group to which no sample was added was set, and as a positive control, a group to which insulin was added so as to have a final concentration of 1 g / mL was set.
- 2-de O Kishi [1, 2- 3 H (N )] was incorporated into the cells - were measured amount of glucose.
- Example 14 Preparation of ethanol extract fraction of 4 ashitapa root and ethyl acetate extract 4 OmL of ethanol or ethyl acetate was added to 2 g of each dried powder of abaca root, and extraction was performed at room temperature for 30 minutes. The extract was separated into an extract and a residue by centrifugation. Then, the extraction operation with 3 O mL of each solvent was repeated twice for the residue. The obtained extracts were collected and concentrated on a rotary evaporator. Finally, the ethanol extract is dissolved in 1 mL of dimethylsulfoxide, and the ethanol extract of Ashitaba root is extracted. Got.
- the differentiation-inducing activity (insulin-like activity) of the ethanol extract fraction of the radish root and the ethyl acetate extract of the radish root prepared in Example 14 on mature adipocytes was determined according to the method of Example 3. Measured.
- a category was set in which a dimethylsulfoxide solution or a citapap root-ethyl acetate-extracted fraction of a citava root ethanol-extracted fraction with a final concentration of 0.05 and 0.025% was added to each well, respectively.
- a category of addition of an aqueous solution of 4 5 mg ZmL insulin (manufactured by Yukara Bio Inc.) was set, and as a negative control, a category of addition of dimethyl sulfoxide was set. Thereafter, the medium and the sample were exchanged in the same manner as in Example 3, and the amount of triglyceride in the cells was measured 7 days after the addition of the sample.
- Example 5 was used as an evaluation of the action of promoting the uptake of dalcose and the evaluation of the insulin-like action of the fraction extracted from the ethanol extract and the extract from the ethyl acetate prepared by the method of Example 14. Samples from mature adipocytes according to the method described The amount of 2-dexoxyglucose uptake into the cells at the time of stimulation was measured.
- a dimethyl sulfoxide solution or a dimethyl sulfoxide solution containing a 0.1% or 0.05% final concentration of an ethyl acetate extract or an ethyl acetate extract was added to each well.
- a negative control a group to which no sample was added was set, and as a positive control, a group to which insulin was added so as to have a final concentration of 1 g ZmL was set.
- incorporated into the cells 2 Dokishi [1, 2- 3 H (N )] - to measure the amount of glucose.
- Example 6 The evaluation of the glucose uptake-promoting action of the ethanol extract fraction of the acitapa leaf and the ethyl acetate extract fraction of the abaca leaf prepared in Example 6 and the evaluation of the insulin-like action were carried out according to the method described in Example 5. The amount of 2-dexoxyglucose uptake into mature adipocytes during sample stimulation was measured.
- a dimethylsulfoxide solution of an ethanol extract fraction of an acacia leaf leaf or a dimethylsulfoxide solution of an ethyl acetate extract fraction of an ashtapa leaf having a final concentration of 0.2% or 0.1% was added to each well.
- a negative control a group to which no sample was added was set, and as a positive control, a group to which insulin was added so as to have a final concentration of 1 g / mL was set.
- 2 Dokishi [1, 2- 3 H (N )] was incorporated into the cells was measured one glucose amount.
- fractionation fraction of silica column with a final concentration of 0.03 mg / mL 1 fractionation fraction of silica column with a final concentration of 0.013 mg / mL 2
- fractionation fraction of silica column with a final concentration of 0.0077 mg / mL fraction 4 of a silica column fraction having a final concentration of 0.0096 mg / mL was used.
- a negative control a group to which no sample was added was set, and as a positive control, a group to which insulin was added so that the final concentration was lg / mL was set.
- incorporated into the cells 2 Dokishi - [1, 2- 3 H ( N)] was measured an amount of glucose.
- cytochalasin B which is a glucose transporter inhibitor
- the mature adipocytes are treated according to the method described in Example 5.
- the effect of cytochalasin B on the uptake of 2-dexoxyglucose into cells during sample stimulation in E. coli was tested.
- a group was added to which a dimethyl sulfoxide solution was added as a sample so that the final concentration of the sample was 0.1%, and the fraction extracted from the ethanol extracted from the ash root was added.
- a negative control a group to which no sample was added was set, and as a positive control, a group to which insulin was added so as to have a final concentration of 1 zgZmL was set.
- a category was added in which cytochalasin B (Nacalai Tesque, Inc., 10435-81) was added so that the final concentration was 40 M at the same time as when the category in which insulin was added was set.
- incorporated into the cells 2 Dokishi [1, 2- 3 H (N )] was measured an amount of glucose.
- sample stimulation with mature adipocytes was carried out in part according to the method described in Example 5. At this time, the amount of 2-dexoxyglucose uptake into the cells was measured.
- a sample to which a dimethyl sulfoxide solution having a final concentration of 0.05% and a fraction of ethanol extracted from radish root was added was set.
- an aqueous solution of 5 mg ZmL insulin (manufactured by Yukara Bio Inc.) of 4 II 1 was set.
- the medium and the sample were exchanged according to the method described in Example 3 except that the final concentration of 0.5 mM 3-isobutyl-1-methylxanthine was added at the same time as the time of addition of dexamethasone.
- Mature adipocytes induced to differentiate by ethanol extraction or insulin were obtained.
- the differentiation-inducing activity (insulin-like activity) of the ethanol extract fraction of the foliage of Ashitapa prepared in Example 22 into mature adipocytes was measured according to the method of Example 3. That is, as a sample, a section was set to which a dimethyl sulfoxide solution of ethanol extract fraction of the stem and leaf ethanol of Ashitaba with a final concentration of 0.2, 0.066, and 0.022% was added. As a positive control, a category of adding an aqueous solution of 5 mg Zml insulin (manufactured by KARA BIO INC.) was set as a positive control, and a category of adding dimethyl sulfoxide was set as a negative control. Thereafter, the medium and the sample were exchanged in the same manner as in the method described in Example 3, and the biosynthesis amount of tridaliceride in the cells was measured 7 days after the addition of the sample.
- One liter of ethanol was added to 200 g of the dried powder of the root of Ashitaba, extracted at room temperature for 30 minutes, filtered with suction, and separated into an ethanol extract and a residue. Then, the residue was subjected to an extraction operation with 1 liter of the same solvent once. The obtained ethanol extract was collected and concentrated at the mouth of the evaporator. The obtained concentrate was dissolved in 100 ml of olive oil to prepare an ethanol extract fraction of the root of the basin.
- a medicament, food, beverage or feed for treating or preventing a disease associated with modulation of the amount of insulin or insulin response, which contains a processed product derived from a Umbelliferae plant as an active ingredient.
- the medicament is useful as a therapeutic or prophylactic agent for diseases associated with modulation of insulin levels or insulin responses such as diabetes or obesity.
- a functional food or drink containing a processed product derived from a Umbelliferae plant is a functional food or drink that is useful for maintaining the homeostasis of a living body due to its insulin-like action.
- the present invention also provides an insulin-like agent containing a processed product derived from a Umbelliferae plant, and the insulin-like agent is useful for studying the function of insulin and for screening a drug for insulin-related diseases. Further, according to the present invention, there is also provided an agent for promoting uptake of darcose into cells containing a processed product derived from a Umbelliferae plant. It is also useful for the treatment or prevention of the disease, the production of foods, drinks or feeds for the treatment or prevention of the disease, and the screening of drugs for the disease requiring the glucose uptake promoting action. In addition, the present invention also provides an agent for inducing differentiation into adipocytes containing a processed product derived from a Umbelliferae plant. It is also useful for prevention, production of foods, drinks or feeds for treating or preventing the disease, and screening of drugs for diseases requiring the differentiation-inducing action.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004527340A JP4751066B2 (ja) | 2002-08-09 | 2003-08-06 | 治療剤 |
AU2003254818A AU2003254818A1 (en) | 2002-08-09 | 2003-08-06 | Remedy |
CA002495419A CA2495419A1 (en) | 2002-08-09 | 2003-08-06 | Remedy |
EP03784533A EP1547608A4 (en) | 2002-08-09 | 2003-08-06 | REMEDIES |
US10/524,015 US20060034949A1 (en) | 2002-08-09 | 2003-08-06 | Remedy |
US11/905,945 US20080044498A1 (en) | 2002-08-09 | 2007-10-05 | Therapeutic or prophylactic agent, and method of treating or preventing a disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-233808 | 2002-08-09 | ||
JP2002233808 | 2002-08-09 | ||
JP2003127518 | 2003-05-02 | ||
JP2003-127518 | 2003-05-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/905,945 Division US20080044498A1 (en) | 2002-08-09 | 2007-10-05 | Therapeutic or prophylactic agent, and method of treating or preventing a disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004014407A1 true WO2004014407A1 (ja) | 2004-02-19 |
Family
ID=31719879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/009978 WO2004014407A1 (ja) | 2002-08-09 | 2003-08-06 | 治療剤 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20060034949A1 (ja) |
EP (1) | EP1547608A4 (ja) |
JP (1) | JP4751066B2 (ja) |
KR (1) | KR20050059059A (ja) |
CN (1) | CN1674926A (ja) |
AU (1) | AU2003254818A1 (ja) |
CA (1) | CA2495419A1 (ja) |
TW (1) | TW200417366A (ja) |
WO (1) | WO2004014407A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010037333A (ja) * | 2008-07-08 | 2010-02-18 | Takara Bio Inc | 経口摂取用組成物 |
JP2015003877A (ja) * | 2013-06-20 | 2015-01-08 | 国立大学法人 筑波大学 | ヒドロキシチロゾール又はその塩を含む組成物 |
JP2017218412A (ja) * | 2016-06-08 | 2017-12-14 | 株式会社アイビー化粧品 | 線維芽細胞の増殖促進剤 |
JP2019156741A (ja) * | 2018-03-09 | 2019-09-19 | 国立大学法人 筑波大学 | 機能性組成物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07322847A (ja) * | 1994-05-30 | 1995-12-12 | Fujimaru Shokuhin Kk | 生わさび様又は粉末わさび様食品の製造方法 |
JPH09121810A (ja) * | 1995-08-03 | 1997-05-13 | Hida Aroe:Kk | キダチアロエ粉末とアシタバ粉末を配合した粒状の健康食品 |
JPH10295325A (ja) * | 1997-04-28 | 1998-11-10 | Katsuji Nagamitsu | 健康食品 |
JP2002080362A (ja) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
JP2002138045A (ja) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | 前駆脂肪細胞分化誘導剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02215354A (ja) * | 1989-02-14 | 1990-08-28 | Sanmi Shoji Kk | あしたば入こんにゃくの製造方法 |
FR2750606B1 (fr) * | 1996-07-03 | 1999-01-29 | Maurel Sante | Complexes organometalliques a base de sitosterols et de diglycerides et compositions pharmaceutiques en contenant |
US6171635B1 (en) * | 1997-05-06 | 2001-01-09 | Iris G Zhao | Coffee substitute |
JP2001252044A (ja) * | 2000-03-15 | 2001-09-18 | Healthy Shokuhin Kk | 五大栄養素調合食品薬膳 |
AU2001246876A1 (en) * | 2000-04-10 | 2001-10-23 | Takara Bio Inc. | Remedies |
-
2003
- 2003-08-06 CA CA002495419A patent/CA2495419A1/en not_active Abandoned
- 2003-08-06 EP EP03784533A patent/EP1547608A4/en not_active Withdrawn
- 2003-08-06 AU AU2003254818A patent/AU2003254818A1/en not_active Abandoned
- 2003-08-06 KR KR1020057002182A patent/KR20050059059A/ko not_active Application Discontinuation
- 2003-08-06 US US10/524,015 patent/US20060034949A1/en not_active Abandoned
- 2003-08-06 JP JP2004527340A patent/JP4751066B2/ja not_active Expired - Fee Related
- 2003-08-06 WO PCT/JP2003/009978 patent/WO2004014407A1/ja active Application Filing
- 2003-08-06 CN CNA03819502XA patent/CN1674926A/zh active Pending
- 2003-08-08 TW TW092121844A patent/TW200417366A/zh unknown
-
2007
- 2007-10-05 US US11/905,945 patent/US20080044498A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07322847A (ja) * | 1994-05-30 | 1995-12-12 | Fujimaru Shokuhin Kk | 生わさび様又は粉末わさび様食品の製造方法 |
JPH09121810A (ja) * | 1995-08-03 | 1997-05-13 | Hida Aroe:Kk | キダチアロエ粉末とアシタバ粉末を配合した粒状の健康食品 |
JPH10295325A (ja) * | 1997-04-28 | 1998-11-10 | Katsuji Nagamitsu | 健康食品 |
JP2002080362A (ja) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
JP2002138045A (ja) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | 前駆脂肪細胞分化誘導剤 |
Non-Patent Citations (4)
Title |
---|
ALISON M. ET AL.: "Insulin-releasing and insulin-like activity of the traditional anti-diabetic plant coriandrum sativum(coriander)", BRITISH J. NUTRITION, vol. 81, no. 3, 1999, pages 203 - 209, XP002975808 * |
BROADHURST C. LEIGH ET AL.: "Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro", J. AGRIC. FOOD CHEM., vol. 48, no. 3, 2000, pages 849 - 852, XP002975810 * |
KEIZO SEKIYA: "Carrot ni hukumareru zenku sibo saibo no bunka chosetsu seibun", SHOKUHIN KENKYU SEIKA JOHO, vol. 9, no. 1, 1997, pages 24 - 25, XP002975809 * |
See also references of EP1547608A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010037333A (ja) * | 2008-07-08 | 2010-02-18 | Takara Bio Inc | 経口摂取用組成物 |
JP2015003877A (ja) * | 2013-06-20 | 2015-01-08 | 国立大学法人 筑波大学 | ヒドロキシチロゾール又はその塩を含む組成物 |
JP2017218412A (ja) * | 2016-06-08 | 2017-12-14 | 株式会社アイビー化粧品 | 線維芽細胞の増殖促進剤 |
JP2019156741A (ja) * | 2018-03-09 | 2019-09-19 | 国立大学法人 筑波大学 | 機能性組成物 |
JP7095861B2 (ja) | 2018-03-09 | 2022-07-05 | 国立大学法人 筑波大学 | 機能性組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20060034949A1 (en) | 2006-02-16 |
AU2003254818A1 (en) | 2004-02-25 |
KR20050059059A (ko) | 2005-06-17 |
JP4751066B2 (ja) | 2011-08-17 |
TW200417366A (en) | 2004-09-16 |
CN1674926A (zh) | 2005-09-28 |
CA2495419A1 (en) | 2004-02-19 |
TWI294284B (ja) | 2008-03-11 |
US20080044498A1 (en) | 2008-02-21 |
EP1547608A1 (en) | 2005-06-29 |
EP1547608A4 (en) | 2007-05-30 |
JPWO2004014407A1 (ja) | 2005-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009269927A (ja) | 治療剤 | |
JPWO2002022140A1 (ja) | 恒常性維持剤 | |
WO2004100969A1 (ja) | 治療剤 | |
TWI239245B (en) | Medical composition for oral administration or intravenous administration for a disease requiring enhancement of nerve growth factor production for treatment or prevention | |
US20060039998A1 (en) | Remedies | |
JPWO2004112817A1 (ja) | セリ科植物由来抽出物およびその製造方法 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
JPWO2006082743A1 (ja) | 治療剤 | |
US20080044498A1 (en) | Therapeutic or prophylactic agent, and method of treating or preventing a disease | |
KR101698201B1 (ko) | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물을 포함하는 근육 증가 촉진, 항-피로 및 운동수행능력 향상용 조성물 | |
KR20160026595A (ko) | 율무, 표고버섯, 탱자 및 옥수수수염의 혼합물을 포함하는 비만 및 비만관련 질환의 예방 또는 개선용 조성물 | |
JP6273440B2 (ja) | Glp−1産生促進剤、dppiv阻害剤及びグルコース吸収阻害剤 | |
KR101257329B1 (ko) | 해삼 추출물을 함유하는 비만 치료 또는 예방용 조성물 | |
KR102217264B1 (ko) | 코디움 속 해조류 추출물을 유효성분으로 포함하는 근육 질환 예방, 개선 또는 치료용 조성물 | |
JPH1149690A (ja) | 脂肪分解促進用組成物 | |
JPWO2008123417A1 (ja) | 抗疲労剤 | |
KR101001159B1 (ko) | 비파 추출물을 함유하는 당뇨병 예방 또는 개선용 조성물 | |
US20070092587A1 (en) | Extract from plant of japanese parsley family and process for producing the same | |
JP2020019756A (ja) | 一酸化窒素産生促進剤 | |
KR20170090972A (ko) | 밀배아 추출물을 포함하는 여성암 억제 및 치료용 조성물 및 이의 제조방법 | |
KR20240077110A (ko) | 청귤 과피 추출물을 유효성분으로 포함하는 비만 또는 이상지질혈증의 예방, 개선 또는 치료용 조성물 | |
KR20220142074A (ko) | 꾸지뽕 열매 추출물 및 굼벵이를 유효성분으로 포함하는 간기능 개선용 조성물 | |
KR20190015423A (ko) | 아위느타리버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
KR20210050085A (ko) | 돌외 및 검정무의 혼합추출물을 포함하는 약학 조성물 | |
KR20190131315A (ko) | 갈색거저리 추출물을 유효성분으로 포함하는 수술 후 회복 촉진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004527340 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2495419 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057002182 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003254818 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006034949 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10524015 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003784533 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003819502X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002182 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003784533 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10524015 Country of ref document: US |